Monte Rosa Therapeutics reported a quarterly loss of $0.43/share, worse than the Zacks Consensus Estimate loss of $0.25/share and down from a loss of $0.15/share a year ago. The results indicate continued earnings deterioration versus both the Street and the prior-year quarter.
Monte Rosa Therapeutics reported a quarterly loss of $0.43/share, worse than the Zacks Consensus Estimate loss of $0.25/share and down from a loss of $0.15/share a year ago. The results indicate continued earnings deterioration versus both the Street and the prior-year quarter.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
